Implication of both exogenous and endogenous AGEs in the pre-cancer risk and incidence, cancer progression and mortality, and post-cancer complications, necessitate the advent of drugs capable of inhibiting the formation of total AGEs and AGE-activated RAGE, as combination agents in cancer chemotherapy for the plausible enhanced advantage. The gene discussed is AGER; the disease is cancer.